Restricted accessResearch articleFirst published online 2011-05
Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients
Palonosetron, a unique second-generation 5-HT3 receptor antagonist, has been demonstrated to control emesis related to chemotherapy-induced nausea and vomiting (CINV). The aim of this study was to evaluate the efficacy and tolerability of palonosetron followed by a single dose of dexamethasone in patients with breast cancer (BC) or colorectal cancer (CRC) receiving moderate emetogenic chemotherapy (MEC).
Methods and study design
Chemotherapy-naive BC and CRC patients were given MEC as adjuvant or first-line treatment. Palonosetron (0.25 mg IV) and dexamethasone (8 mg IV) were administered before chemotherapy on day 1. The primary endpoint was complete response (CR; no vomiting and no use of rescue medication) during the overall study period (days 1–5). The antiemetic response was evaluated during the acute (day 1) and delayed (days 2–5) phases.
Results
Sixty-eight patients were enrolled (median age 61 years, 56 females; BC = 40, CRC = 28). CR was observed in 46 of 68 patients (67.6%), while CR during the acute and delayed phases was 75.0% in each cancer group. The antiemetic regimen was well tolerated.
Conclusions
A single administration of palonosetron and dexamethasone on day 1 in BC and CRC patients adequately controls CINV during the entire period of emetic risk.
Roila F, Hesketh PJ, Herrstedt J; Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer:Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia International Antiemetic Consensus Conference.Ann Oncol, 17: 20–28, 2006.
7.
WaltonS.M.: Advances in use of the 5-HT3 receptor antagonists.Expert Opin Pharmacother, 1: 207–223, 2000.
8.
RoilaF., BallatoriE., TonatoM., Del FaveroA.: 5-HT3 receptor antagonists: differences and similarities.Eur J Cancer, 33: 1364–1370, 1997.
9.
AaproM.S.: Palonosetron as an anti-emetic and anti-nausea agent in oncology.Ther Risk Clin Manag, 3: 1009–1020, 2007.
IoannidisJ.P., HeskethP.J., LauJ.: Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence.J Clin Oncol, 18: 3409–3422, 2000.
GrunbergS.M.: Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis.Ann Oncol, 18: 233–240, 2007.
15.
VardyJ., ChiewK.S., GalicaJ., PondG.R., TannockI.F.: Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy.Br J Cancer, 94: 1011–1015, 2006.
16.
GrallaR., LichinitserM., Van derVegtS., SleeboomH., MezgerJ., PeschelC., ToniniG., LabiancaR., MacciocchiA., AaproM.: Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.Ann Oncol, 14: 1570–1577, 2003.
17.
AaproM.S., GrunbergS.M., ManikhasG.M., OlivaresG., SuarezT., TjulandinS.A., BertoliL.F., YunusF., MorricaB., LordickF., MacciocchiA.: A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.Ann Oncol, 17: 1441–1449, 2006.
18.
Eisenberg P, Figuero-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99-04 Palonosetron Study Group:Improved prevention of moderately emetogenic chemotherapy induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist. Results of a phase III, single dose trial versus dolasetron.Cancer, 98: 2473–2482, 2003.
19.
SaitoM., AogiK., SekineI., YoshizawaH., YanagitaY., SakaiH., InoueK., KitagawaC., OguraT., MitsuhashiS.: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.Lancet Oncol, 10: 115–124, 2009.
20.
HeskethP.J., KrisM.G., GrunbergS.M., BeckT., HainsworthJ.D., HarkerG., AaproM.S., GandaraD., LindleyC.M.: Proposal for classifying the acute emetogenicity of cancer chemotherapy.J Clin Oncol, 15: 103–109, 1997.
21.
FlemingT.R.: One sample multiple testing procedure for phase II clinical trials.Biometrics, 38: 143–151, 1982.
22.
Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, on behalf of the ESMO/MASCC Guidelines Working Group:Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference.Ann Oncol, 21(Suppl 5): v232–v243, 2010.
23.
AaproM., FabiA., NolèF., MediciM., StegerG., BachmannC., RoncoroniS., RoilaF.: Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.Ann Oncol, 21: 1083–1088, 2010.
24.
Celio L, Frustaci S, Denaro A, Buonadonna A, Ardizzoia A, Piazza E, Fabi A, Capobianco AM, Isa L, Cavanna L, Bertolini A, Bichisao E, Bajetta E, for the Italian Trials in Medical Oncology Group:Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial.Support Care Cancer, Jun 25 [Epub ahead of print], 2010.
25.
YinL., LiY.B., WangY.S.: Dexamethasone-induced adipogenesis in primary marrow stromal cell cultures: mechanism of steroid-induced osteonecrosis.Chin Med J (Engl), 119: 581–588, 2006.
JakobsenJ.N., HerrstedtJ.: Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patientsCrit Rev Oncol Hematol, 71: 214–221, 2009.
28.
GiulianiF., CilentiG., NugnesI., MaielloE., Di BisceglieM., LorussoV., AdamoV., ColucciG.: Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: a phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).Eur J Cancer Suppl, 6: 102–106, 2008.
29.
GrunbergS.M., DuganM., MussH., WoodM., Burdette-RadouxS., WeisbergT., SiebelM.: Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.Support Care Cancer, 17: 589–594, 2009.
